U.S. President Donald Trump signed an executive order on Monday that aims to reduce the time it takes to approve pharmaceutical plants in the country, as part of new regulations to encourage domestic manufacturing.

President Donald Trump on Monday signed an executive order to incentivize drug manufacturing in the U.S., streamlining the path for pharmaceutical companies to build new production sites stateside.

The order directs the U.S. Food and Drug Administration to reduce the time it takes to approve drug manufacturing plants in the country, as well as to increase fees for inspections at foreign sites, according to the newspaper.